TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis
TransCode Therapeutics (NASDAQ: RNAZ) reported publication of a peer-reviewed study in Cancers showing its lead candidate TTX-MC138 produced significant survival benefits in a preclinical mouse model of breast cancer bone metastasis.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TransCode Therapeutics (NASDAQ: RNAZ) reported publication of a peer-reviewed study in Cancers showing its lead candidate TTX-MC138 produced significant survival benefits in a preclinical mouse model of breast cancer bone metastasis. According to TransCode, systemically administered TTX-MC138 accumulated in metastatic bone lesions, reduced expression of metastasis‑linked microRNA‑10b (miR‑10b), and increased expression of the tumor‑suppressor target HOXD10.
The study also found repeated dosing was well tolerated with no observed systemic toxicity, supporting the use of image‑guided anti‑miR‑10b nanotherapeutics as a potentially translatable approach for metastatic cancer. TransCode said the findings may inform future applications beyond its current clinical focus in colorectal cancer.
Positive
- Preclinical survival benefit with TTX-MC138 in breast cancer bone metastasis model
- Target engagement shown via reduced miR-10b and increased HOXD10 expression
- Favorable tolerability with repeated dosing and no observed systemic toxicity
- Bone lesion accumulation demonstrated after systemic administration of TTX-MC138
- Potential expansion of miR-10b inhibition strategy to additional metastatic settings
Negative
- Evidence limited to preclinical mouse model, with no human efficacy data reported yet
- Current clinical focus remains colorectal cancer, so breast cancer bone metastasis use is only prospective
Details
Market move: RNAZ -3.67% in the Aug 31 session. preclinical survival data
On Aug 31, the day this news came out, RNAZ closed 3.67% below the previous close. Argus tracked a peak move of +21.4% during that session. Argus tracked a trough of -26.7% from its starting point during tracking. Our momentum scanner recorded 31 alerts for this stock that day. Relative volume reached 21.0x the daily average during tracking.
Data tracked by StockTitan Argus for the Aug 31 session.
Key Figures
- Announcement date
- August 31, 2026
- News announcement
- Publication date
- August 23, 2026
- Cancers peer-reviewed oncology journal
Historical Context
-
Company announced its first R&D webcast covering TTX-MC138 and its broader therapeutic pipeline.
-
Phase 1a trial reported safety, stable disease, and a recommended Phase 2a dose.
-
Company initiated a Phase 2a colorectal cancer trial planning enrollment of up to 45 patients.
-
Company entered financing agreements providing access to up to $20 million.
-
TransCode secured an exclusive worldwide license through an all-stock transaction.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
microRNA-10b medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Published study in Cancers highlights therapeutic potential of targeting microRNA-10b in bone metastasis with TransCode's lead therapeutic candidate
The publication builds on a growing body of evidence supporting microRNA-10b (miR-10b) as an important driver of cancer metastasis and further validates TransCode's therapeutic approach of inhibiting miR-10b using proprietary oligonucleotide nanotechnology.
The study was led by Dr. Anna Moore, Professor in the Radiology and Physiology Departments, Director of the Precision Health Program and Associate Dean for Research Development at the College of Human Medicine at Michigan State University. Dr. Moore is a co-founder of TransCode Therapeutics and Chair of the Scientific Advisory Board, and a globally recognized expert in molecular imaging and RNA-targeted cancer therapeutics.
"Metastatic disease remains responsible for the overwhelming majority of cancer deaths, and effective therapies specifically designed to target metastasis remain limited," said Zdravka Medarova, Ph.D., Chief Scientific Officer of TransCode Therapeutics and co-author of the publication. "These findings demonstrate that miR-10b inhibition can significantly impact survival in a challenging model of metastatic cancer and further support the potential applicability of our platform across multiple metastatic tumor types."
Key Findings
Among the study's findings:
- TTX-MC138 successfully accumulated in metastatic bone lesions in a mouse model of bone cancer bone metastasis following systemic administration.
- Treatment significantly reduced expression of miR-10b, a microRNA implicated in metastatic progression, and increased expression of HOXD10, a downstream tumor-suppressor target.
- Animals treated with anti-miR-10b therapeutics demonstrated significant survival benefits compared with controls.
- Repeated dosing was well tolerated, with no evidence of systemic toxicity observed during the study.
- The results support the use of image-guided anti-miR-10b nanotherapeutics as a potentially translatable strategy for treating metastatic cancer.
Bone is the most common site of metastatic spread in breast cancer and represents a major unmet medical need, with patients experiencing substantial morbidity and poor long-term outcomes. The authors concluded that targeting miR-10b using an image-guided anti-miR-10b nanotherapeutic represents a promising and translatable strategy for treating breast cancer bone metastases.
Relevance to TransCode's Clinical Program
While TransCode's current clinical development efforts are focused on metastatic cancers and its ongoing TTX-MC138 program in molecular residual disease-positive colorectal cancer, the newly published findings suggest potential future applicability of miR-10b inhibition across additional metastatic disease settings where tumor spread drives poor outcomes.
The article was published online on August 23, 2026, in Cancers, a peer-reviewed oncology journal.
About TTX-MC138
TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. TransCode's Phase 1a first-in-human clinical trial achieved its primary safety endpoint and established a recommended Phase 2 dose, as announced at ESMO 2025.
About TransCode Therapeutics
TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA therapeutic treatments for high risk and advanced cancers. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. For more information, visit www.transcodetherapeutics.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the potential significance of the preclinical findings described in the publication and the therapeutic potential of targeting microRNA-10b with TTX-MC138 across multiple metastatic tumor types. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that the results of clinical trials will not be consistent with TransCode's preclinical studies or expectations or with results from previous clinical trials; risks associated with the conduct of clinical trials; risks associated with TransCode's financial condition and its need to obtain additional funding to support its business activities, including TransCode's ability to continue as a going concern; risks associated with the timing and outcome of TransCode's planned regulatory submissions; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for similar uses; risks associated with TransCode's dependence on third parties; and risks associated with geopolitical events and pandemics. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode's actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled "Risk Factors" in TransCode's Annual Report on Form 10-K for the year ended December 31, 2025, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this release; TransCode undertakes no duty to update this information unless required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/transcode-therapeutics-announces-publication-demonstrating-survival-benefit-of-ttx-mc138-in-preclinical-model-of-breast-cancer-bone-metastasis-302864473.html
SOURCE TransCode Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.